Literature DB >> 23273666

How to select the optimal therapy for early-stage prostate cancer.

Marisa A Kollmeier1, Michael J Zelefsky.   

Abstract

Selecting the "optimal therapy" for the patient with localized prostate cancer may be one of the most challenging medical decisions facing the oncologist. Most patients will have a number of appropriate therapeutic options available to them. Before determining which therapy is most appropriate for a patient, a critical question which needs to be asked is whether any therapy is necessary, especially for those who present with early-stage, low-grade, low-volume disease. Furthermore, given the lack of randomized trials available to guide physicians regarding the superiority of one therapy over another, it is important to consider the different side-effect profiles relevant for each treatment modality. The potential toxicities of therapy impact quality-of-life outcomes and play an important role for most patients in their individual selection of a particular therapy. In addition, there are other important issues that need to be considered, which include the medical condition of the patient and emotional and psychological considerations, as well as family/peer viewpoints or perceived notions of a particular therapy. This review will discuss the relevant issues in the decision making and treatment selection for the patient.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23273666     DOI: 10.1016/j.critrevonc.2012.12.002

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  10 in total

1.  [Evaluation of a prostate cancer E‑health tutorial : Development and testing of the website prostata-information.ch].

Authors:  R Schaffert; U Dahinden; T Hess; A Bänziger; P Kuntschik; F Odoni; P Spörri; R T Strebel; J Kamradt; G Tenti; A Mattei; M Müntener; S Subotic; H-P Schmid; P Rüesch
Journal:  Urologe A       Date:  2018-02       Impact factor: 0.639

2.  Incongruence in treatment decision making is associated with lower health-related quality of life among prostate cancer survivors: results from the PiCTure study.

Authors:  Frances J Drummond; Anna T Gavin; Linda Sharp
Journal:  Support Care Cancer       Date:  2017-12-08       Impact factor: 3.603

Review 3.  An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy.

Authors:  R G Bristow; A Berlin; A Dal Pra
Journal:  Br J Radiol       Date:  2014-02-03       Impact factor: 3.039

4.  Usability evaluation and adaptation of the e-health Personal Patient Profile-Prostate decision aid for Spanish-speaking Latino men.

Authors:  Donna L Berry; Barbara Halpenny; Jaclyn L F Bosco; John Bruyere; Martin G Sanda
Journal:  BMC Med Inform Decis Mak       Date:  2015-07-24       Impact factor: 2.796

5.  Controlling RECK miR21 Promotes Tumor Cell Invasion and Is Related to Biochemical Recurrence in Prostate Cancer.

Authors:  Katia R M Leite; Sabrina T Reis; Nayara Viana; Denis R Morais; Caio M Moura; Iran A Silva; José Pontes; Betina Katz; Miguel Srougi
Journal:  J Cancer       Date:  2015-01-21       Impact factor: 4.207

Review 6.  Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer.

Authors:  Kristine M Wadosky; Shahriar Koochekpour
Journal:  Int J Biol Sci       Date:  2016-02-06       Impact factor: 6.580

Review 7.  Androgen receptor splice variants and prostate cancer: From bench to bedside.

Authors:  Kristine M Wadosky; Shahriar Koochekpour
Journal:  Oncotarget       Date:  2017-03-14

Review 8.  Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.

Authors:  Kristine M Wadosky; Shahriar Koochekpour
Journal:  Oncotarget       Date:  2016-09-27

9.  Quantitative imaging parameters to predict the local staging of prostate cancer in intermediate- to high-risk patients.

Authors:  Riccardo Laudicella; Stephan Skawran; Daniela A Ferraro; Urs J Mühlematter; Alexander Maurer; Hannes Grünig; Hendrik J Rüschoff; Niels Rupp; Olivio Donati; Daniel Eberli; Irene A Burger
Journal:  Insights Imaging       Date:  2022-04-15

10.  Efficacy and toxicity of external-beam radiation therapy for localised prostate cancer: a network meta-analysis.

Authors:  Z Zhu; J Zhang; Y Liu; M Chen; P Guo; K Li
Journal:  Br J Cancer       Date:  2014-04-15       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.